ACXP — Acurx Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1736243 ·
Last close
$0.99
Market Cap
$6.00M
52W High
$7.54
52W Low
$0.90
ADV30
101,096
Next earnings
2026-11-12
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,307,228 -2,254,173 10,984,777 10,656,386 2,832,746
Mar 2026 0 — -1,715,990 -1,680,982 9,539,952 9,254,813 2,526,809
Dec 2025 0 — -1,617,116 -1,578,276 7,689,535 7,556,100 2,420,943
Sep 2025 0 — -2,028,701 -1,992,790 6,105,211 5,906,802 2,468,175

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,183,194
Investing CF
—
Financing CF
$10,775,452
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.27
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-79,223,649
Inventory
—
Receivables
$95,307
ST Investments
—
EBIT TTM
$-7,669,035
Pretax Income TTM
$-7,506,221
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -8,091,983 -7,966,538 7,689,535 2,420,943 5,268,592 -6,787,782
Dec 2024 0 -14,123,227 -14,103,103 3,857,963 3,242,842 615,121 -10,383,431
Dec 2023 0 -14,577,768 -14,577,768 7,709,123 3,042,438 4,666,685 -9,800,885
Dec 2022 0 -12,092,776 -12,092,776 9,376,706 2,061,685 7,315,021 -7,542,290

TTM Snapshot

Revenues TTM
$190,104
NetIncome TTM
$-7,506,221
OpCashFlow TTM
—
Assets (Latest)
$10,984,777
Forward EPS
$-1.78

Peers — same industry

TickerNameMarket CapLastDaily %
FBLG FibroBiologics, Inc. $6.00M $0.90 —
CNSP CNS Pharmaceuticals, Inc. $6.07M $4.15 —
SNGX SOLIGENIX, INC. $6.11M $0.28 —
INNPF INNOCAN PHARMA Corp $5.80M $1.29 —
GTBP GT Biopharma, Inc. $5.74M $3.18 —

News headlines (Yahoo Finance, 1h cache)

Acurx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:00 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
2026-11-12 12:01 · Yahoo
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
2026-10-26 12:01 · Yahoo
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
2026-10-21 12:01 · Yahoo
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
2026-10-05 17:25 · Yahoo
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
2026-09-29 12:01 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi
2026-09-14 12:01 · Yahoo
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
2026-08-21 01:02 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
2026-08-14 11:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.